

PRESS RELEASE

Camurus to present at Jefferies London Healthcare Conference

Lund, Sweden — 12 November 2025 — Camurus (NASDAQ STO: CAMX) will attend the Jefferies Global Healthcare Conference in London 17–20 November. President and CEO Fredrik Tiberg will present on 18 November at 9.30 am CET, giving an update on the company's recent developments.

A webcast of the presentation can be accessed via:

<https://www.com/webcast/jeff332/register.aspx?conf=jeff332&page=camx&url=https://www.com/webcast/jeff332/camx/1839403>

For more information

Fredrik Joabsson, Chief Business Development Officer

Tel. +46 (0)70 776 17 37

ir@camurus.com

About Camurus

Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and [LinkedIn](#).

This information was submitted for publication at 10:00 am CET on 12 November 2025.